# Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA

> **NCT02295774** · PHASE2 · COMPLETED · sponsor: **Cosmo Technologies Ltd** · enrollment: 10 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **PROCEDURE:** standard white light colonoscopy-equivalent to placebo
- **DRUG:** Methylene Blue MMX tablets

## Key facts

- **NCT ID:** NCT02295774
- **Lead sponsor:** Cosmo Technologies Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02295774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02295774, "Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02295774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*